Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors

Kerstin Kapp, Barbara Volz, Detlef Oswald, Burghardt Wittig, Matthias Baumann, and Manuel Schmidt

ABSTRACT
Activation of Toll-like receptor 9 (TLR9) is known to foster innate and adaptive immune responses and thus improve immune-mediated control of malignant disease. Lefitolimod is a potent TLR9 agonist without chemical modification developed for immunotherapeutic strategies. Modulation of the tumor microenvironment (TME) is a crucial requirement for the response to various immunotherapies: Immunogenic (“hot”) tumors, characterized by their T cell-infiltrated TME, respond better compared to non-immunogenic (“cold”) tumors. It has been speculated that the mode-of-action of lefitolimod provides the necessary signals for activation of immune cells, their differentiation into anti-tumor effector cells and their recruitment into the TME. We investigated the effect of lefitolimod on TME, and its potency to induce synergistic anti-tumor effects when combined with immune checkpoint inhibitory antibodies (CPI) in a murine model. Indeed, we could show that treatment with single-agent lefitolimod beneficially modulated the TME, via infiltration of activated CD8+ cells and a shift in the macrophage population toward M1 phenotype. The result was a pronounced anti-tumor effect correlated with the magnitude of infiltrated immune cells and tumor-specific T cell responses. In line with this, lefitolimod led to persistent anti-tumor memory in the EMT-6 model after tumor re-challenge. This was accompanied by an increase of tumor-specific T cell responses and cross-reactivity against different tumor cells. Lefitolimod clearly augmented the limited anti-tumor effect of the CPI anti-PD1 in an A20 and anti-PD-L1 in a CT26 model. These properties of potent immune surveillance reactivation render lefitolimod an ideal candidate as therapeutic agent for immuno-oncology, e.g. improving CPI strategies.

Introduction
Toll-like receptors (TLR) belong to the group of pattern recognition receptors (PRR) and recognize pathogen-associated molecular patterns (PAMP). PAMP can be subdivided into different classes of molecules like lipopolysaccharides or pathogen-specific nucleic acids and are ubiquitously present in pathogens but are essentially absent in vertebrates. TLR play a key role in immediate immune responses by enabling immune cells to fight pathogens via the innate immune system. This is followed by the induction of antigen-specific effector T cells as well as memory T cells of adaptive immunity. Therefore, TLR agonists are attractive candidates for the development of therapeutic immune modulators to treat a broad range of diseases like cancer, asthma, allergies, or infections.

TLR9 is predominantly expressed by plasmacytoid dendritic cells (pDC) and B cells and recognizes non-methylated CG-motifs as PAMP, which are present in pathogenic DNA, but underrepresented in human/vertebrate nuclear DNA. TLR9 is known to broadly activate both the innate and adaptive immunity. Therefore, TLR9-triggered immune activation can re-activate immune surveillance to recognize tumor-specific antigens on cancer cells of tumor patients. This translates into the induction of an immune response resulting in the elimination of tumor cells. Synthetic DNA-molecules containing non-methylated CG-motifs function as TLR9 agonists by mimicking the DNA of pathogens and trigger a wide range of immunological activities and are being used for immunotherapeutic approaches.

Members of the dSLIM family (dSLIM: double Stem Loop Immunomodulator), a new family of TLR9 agonists, consist of dumbbell-shaped, covalently closed DNA molecules devoid of any chemical or other artificial modifications of the DNA. Protection against nucleolytic degradation is achieved by the covalently closed structure avoiding accessible 3’ ends. Lefitolimod (MGN1703) belongs to this group of TLR9 agonists exhibiting a specific immunomodulatory sequence and clinical applications. It has been recently been published.

Intracellular signaling triggered by TLR9 results in up-regulation of two pathways: (a) activation of the nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB)
inducing the production of pro-inflammatory cytokines and acquisition of antigen-presenting function, and (b) activation of interferon (IFN) regulatory factor 7 (IRF7) leading to type I IFN (e.g. IFN-alpha) production.14,15 IFN-alpha is crucial for the link of the stimulated innate response to the adaptive arm of the immune system.16 The immunomodulatory potential of lefitolimod has been extensively studied in vitro in human PBMC and subpopulations thereof: Lefitolimod activates TLR9-expressing pDC and B cells. IFN-alpha is secreted by pDC and orchestrates cell signaling like cytokine production and expression of co-stimulatory molecules necessary for the activation of dendritic cells, cytotoxic T-lymphocytes, NK-cells, monocytes, and B-cells, which are known to be important in tumor recognition and killing.8,9,17 This mode-of-action (MoA) was confirmed by (i) use of lefitolimod variants devoid of CG-motifs and therefore unable to recognize TLR9, (ii) using human PBMC depleted of TLR9-positive pDC and (iii) blocking of the type I interferon pathway.5,18 Immune activation by lefitolimod was also confirmed in mice and cynomolgus monkeys. It was speculated that the MoA of lefitolimod starts upstream of the initiation points of immune checkpoint inhibitors (CPI)19 so that a treatment strategy combining both agents, lefitolimod and CPI may result in enhanced anti-tumor effects. Here, we investigate the effects of lefitolimod on the tumor microenvironment (TME) in a murine model, on its potency to induce synergistic anti-tumor effects when combined with CPI as well as its potency to induce long-term immune memory in mouse tumor models.

Results

Impact of lefitolimod on the tumor microenvironment

The syngeneic colon carcinoma model CT26 known as tumor model for microsatellite-stability (MSS),20,21 was used to evaluate lefitolimod’s ability to modulate the tumor microenvironment (TME) and thus induce anti-tumoral effects in vivo (Figure 1(a)). Intratumoral (itu) injection of lefitolimod into established tumors resulted in an increased infiltration of CD3+ T cells into the tumor (Figure 1(d,e)). The subpopulation of CD8+ T cells was increased in the tumor center of the lefitolimod-treated mice (Figure 1(f,g)) and consequently correlated with an inhibition of tumor growth (Figure 1(b,c); Figure S1 (a)). The increase of CD8+ T cells within the tumor observed via immunohistopathology was confirmed by flow cytometry. The CD8+ T cells showed an up-regulation of the cytolytic effector Granzyme B, and are so-called activated CD8+ T cells with cytolytic function (Figure 1(h–k)). Moreover, lefitolimod led to an increase of anti-tumoral M1 macrophages and a decrease of pro-tumoral M2 macrophages inside the TME (Figure 2). A higher ratio of M1/M2 correlated with lower tumor volume (Figure S1(b)).

Generation of tumor-specific CD8 + T cells

Itu treatment with lefitolimod in the syngeneic colon carcinoma model CT26 was used to evaluate lefitolimod’s ability to induce a systemic tumor-specific immune response. Splenocytes from lefitolimod-treated mice were re-stimulated with CT26 cells or the MHC-I restricted AH1 peptide derived from the immunodominant antigen gp-70 of CT26 cells. A significant increase of IFN-gamma secreting cells was detected in the spleens of lefitolimod-treated mice after re-stimulation with CT26 cells in comparison to vehicle-treated mice (Figure 3(a)). Moreover, an increase of IFN-gamma secreting cells within the spleens of lefitolimod-treated mice was detected after re-stimulation with the tumor-specific AH1 peptide antigen (Figure 3(b)), indicating the generation of a systemic tumor-specific CD8+ T cell response. The magnitude of response correlated inversely with the measured tumor volume in the lefitolimod-treated group (Figure 3(c,d)).

Anti-tumor effects of lefitolimod in low-immunogenic B16 melanoma model

Following the data from CT26 colon carcinoma model, we investigated the effect of lefitolimod in the B16 melanoma model known as low-immunogenic.22 Subcutaneous treatment with lefitolimod led not only to reduced tumor growth but this also translated well into augmented survival (Figure 4(a–d)). The results suggest that lefitolimod is able to reactivate the immune surveillance against another tumor of low immunogenicity.

Induction of tumor regression and long-lasting immune memory by lefitolimod in EMT-6 breast cancer model

The EMT-6 breast cancer model, described as more immunogenic in comparison to CT26 and B16 but with a comparable degree of low immune cell infiltration,23 is non-responsive to immunotherapy, i.e. with anti-PD-L1.24 However, treatment of mice with single-agent lefitolimod in the syngeneic EMT-6 breast cancer model showed substantial tumor growth inhibition and a highly significant increase of survival (Figure 4(e,f)). Notably, the tumors of 9/10 mice completely disappeared. All nine mice survived a second inoculation of EMT-6 cells as well, in contrast to age-matched naive mice, indicating a sustained anti-tumor immune memory against EMT-6 tumor cells. Furthermore, all nine mice survived a subsequent inoculation with a distinct CT26 colorectal cancer cell line (Figure 4(g)). This indicates that lefitolimod was not only able to induce a sustained anti-tumor immune memory against EMT-6 tumor cells, but also generated a comprehensive immune response against other cell type, such as CT26 tumor cells, likely via shared antigens of both tumor types. Higher numbers of IFN-gamma secreting cells were detected after stimulation of splenocytes from the double-surviving mice with EMT-6 and CT26, but also with Renca (renal cancer) and 4T1 (breast cancer) cells in comparison to spleen cells of age-matched controls (Figure 4(h)). This indicates the generation of a broad systemic immune memory.

Indirect anti-tumor effect of lefitolimod

To evaluate if a direct effect of lefitolimod on tumor cells contributed to the observed anti-tumor effect, lefitolimod’s influence on the viability of selected tumor cell lines was studied – i.e. cell lines used for tumor inoculation in previously employed tumor models (EMT-6, B16F10, CT26,
A20). Neither lefitolimod nor a lefitolimod variant without functional CG-motifs showed relevant induction of cytotoxicity in a relevant concentration range (even at higher concentrations than necessary for optimal immune activation in vitro) (Figure S2). The results were confirmed in an apoptosis-assay, where no increase of caspase 3/7 activity was detected after treatment of the relevant tumor cell lines with lefitolimod (data not shown). This confirmed that lefitolimod does not directly reduce the viability of the tumor cells. Reduced growth of tumor cells required further components of the immune system, such as pDC and NK cells.\textsuperscript{8,10}

**Combination of lefitolimod with checkpoint inhibitors in syngeneic tumor models**

It was speculated that the mode-of-action of lefitolimod starts upstream of the initiation points of immune checkpoint inhibitors (CPI) like anti-PD-1/anti-PD-L1 so that a treatment strategy combining both agents, lefitolimod and CPI, may result in an enhanced anti-tumor effect. Using the previously employed colon carcinoma CT26 model the combined treatment with lefitolimod and anti-PD-L1 led to a further reduction in tumor growth and also to a prolonged survival of the mice (Figure 5(a,b)). The synergistic anti-tumor effect of lefitolimod with a checkpoint inhibitor was even more pronounced in the A20 lymphoma model, which was selected as model of hematologic origin. The combined treatment with lefitolimod and anti-PD-1 resulted in complete disappearance of the tumors and tumor-free survival of all mice (Figure 5(c,d)). To immunologically explain these anti-tumor data, the impact of lefitolimod on T cell responses was analyzed employing an in vitro assay using human PBMC which were treated with peptides selected from HLA class I-restricted T-cell epitopes of recall-antigens (CMV, EBV, Flu = CEF), lefitolimod and anti-PD-1 as checkpoint inhibitor. The combination of
lefitolimod and anti-PD-1 augmented IFN-gamma secretion of PBMC by about 5–6-fold (single agent lefitolimod: 3-fold, single-agent anti-PD-1: 2-fold) (Figure 5(e)). These data suggest that lefitolimod alone can enhance the activation of CD8+ T cells, but also has the potential to synergistically improve the effect of the checkpoint inhibitor anti-PD-1 (Figure 5(f)).

**Discussion**

Lefitolimod is a TLR9 agonist and triggers the secretion of IFN-alpha by TLR9-expressing pDC. IFN-alpha stimulates several key regulatory immune cells and thereby initiates innate and also adaptive immune responses, the latter specially by activating CD8-alpha dendritic cells able to cross-present antigens to cytotoxic T cells. Activated cytotoxic T cells express the CXC-chemokine receptor 3 (CXCR3), and can migrate into tumors in response to the TH1-type chemokines CXC-chemokine ligand 9 (CXCL9) and IP-10 (CXCL10). Lefitolimod induces the secretion of the chemokine IP-10 from human PBMC. Secretion of IP-10 depends on the presence of pDC and IFN-alpha.

The presence of a T cell-inflamed TME in so-called "hot tumors" is linked with improved responses to cancer immunotherapies including checkpoint inhibitors. However, MSS cancers are characterized by a lower infiltration of T cells and are known to be poorly responsive to CPI rendering it as an ideal model for immunotherapeutic approaches to modulate the TME and enhance the effect of CPI.

Indeed, lefitolimod has shown to activate cytotoxic T cells and initiating their recruitment into the TME in the MSS colon carcinoma CT26 model. These data indicate that the mode-of-action of lefitolimod via TLR9 starts upstream of the targets of checkpoint inhibitors like anti-PD-1/anti-PD-L1.

The combination of lefitolimod with the CPI anti-PD-1/anti-PD-L1 resulted in synergistic anti-tumor effects in mouse tumor models. Similar data have recently been obtained by PTO-modified TLR9 agonists in mice and also in a clinical trial in advanced melanoma. However, it should be considered that PTO-modified TLR9 agonists induce a different cytokine pattern in vitro.

The described immunomodulatory effects of lefitolimod, the potent synergistic anti-tumor responses observed in combination with CPI in murine models, during which no signs of toxicological effects have been observed, and the absence of toxic effects in more than 450 patients in clinical trials renders lefitolimod as an ideal combination partner for immunotherapeutic approaches in humans. In fact, a clinical trial in melanoma patients with a combination of lefitolimod and ipilimumab is ongoing and has shown encouraging first data on increase of tumor-infiltrating lymphocytes and a favorable safety profile, and no dose-limiting toxicities have been encountered at any dose level of lefitolimod together with ipilimumab.
Lefitolimod induced an increase of immune cells within the tumors, shown for T cells as well as for macrophages. Moreover, the ratio of anti-tumoral M1 vs pro-tumoral M2 macrophages\textsuperscript{39,40} was increased after treatment with lefitolimod. The complexity of the population of tumor-associated macrophages is high and they play a dual role in tumor growth. They have anti-tumor features in the early stages of tumors, whereas with tumor progression, tumor-associated macrophages (TAM) adopt a tumor-promoting M2-like phenotype characterized by activation of Th2 signaling in the TME.\textsuperscript{41,42} There is also growing evidence that specific populations of monocytes/macrophages are correlated with improved responses to CPI\textsuperscript{43,44} in humans. Therefore, a promising therapeutic strategy would be the specific targeting of pro-tumoral M2 macrophages or repolarizing M2-like TAM to the tumor-suppressive phenotype.\textsuperscript{41,42}

In our murine models, the strongest anti-tumor effect was observed in the EMT-6 breast cancer model after treatment with lefitolimod showing a complete tumor disappearance in 9/10 mice. The complete regression of established tumors in the immune-excluded EMT-6 model is especially remarkable. In the hands of others, therapeutic blockade of PD-L1 in the EMT-6 model resulted in an anti-tumor effect only in combination with anti-TGF-beta.\textsuperscript{24} Moreover, all surviving mice rejected not only the initially used EMT-6 tumor cells in a re-challenge study, but also the distinct CT26 colorectal cancer cells. The detection of IFN-gamma secreting cells with reactivity not only against EMT-6 and CT26, but also Renca and 4T1 cells in the surviving mice indicate a sustained and broad immune memory after potent initial anti-tumor responses, potentially against shared antigens between different tumor types.

Reduction of tumor growth was shown in the colon carcinoma CT26 model after itu injection of lefitolimod into established tumors. In the clinical setting, tumor burden at the start of treatment have an influence on the benefit from the treatment, with early treatment and smaller tumors being advantageous.\textsuperscript{45,46} In keeping with this, we observed the expected augmented anti-tumor effect in a tumor model when inoculating a lower dose of CT26 cells for tumor growth (Figure S3(a–c)). Furthermore, an earlier treatment – starting as early as 8 days before tumor inoculation – led to clearly better tumor inhibition (Figure S3).

It is also known that itu injection of immunotherapeutic compounds induces potent anti-tumoral immune responses.\textsuperscript{47} This is line with our data (Figure 1, Figure 4(e–h)). The underlying MoA may be a local priming of immune cells like APC present in the tumor which in turn take up, process and present available TAA.\textsuperscript{47,48} However, the itu approach has several clinical limitations: (i) itu administration may be associated with adverse events such as local inflammation, pain, and bleeding;\textsuperscript{49,50} (ii) not all tumor lesions are easily assessable and for the majority of patients with solid cancer, and (iii) additional clinical/surgical/radiological or other imaging methods are required to achieve accurate injection of the
Interestingly, we observed anti-tumor effects also after peritumoral and even distant sc injection of lefitolimod (Figure S5(a) and S4). Supposedly, systemically applied lefitolimod stimulates pDC patrolling within the skin or draining lymph nodes and – after direct activation – leading to their migration to the secondary lymphoid organs triggering immune activation and cell differentiation followed by their migration into the tumor to initiate anti-tumor immune responses. This was recently shown in HIV patients who developed augmented type-I IFN responses in gut biopsies after sc lefitolimod administration. This data supports a clinical strategy of sc lefitolimod administration.

To support the anti-tumor effects obtained from syngeneic models, we employed a skin painting model which mimics the de novo development of tumors mimicking more closely the cancer progression in patients and investigated the tumor prophylactic activity of sc or ip injection of lefitolimod (Figure S5(a)). A reduction in tumor incidence and multiplicity as well as increase of tumor-free survival was observed for animals treated with lefitolimod for both injection routes (Figure S5(b–d)) confirming the previously described anti-tumor effect of lefitolimod in a de novo tumor model.

In summary, we have shown that single-agent lefitolimod has the potential to beneficially modulate the TME, increase...
tumor-specific T cell responses and anti-tumor memory, resulting in pronounced anti-tumor effects. These properties of a potent immune surveillance reactivator improve the effect of CPI and are the basis for combination approaches of lefitolimod with anti-PD-1 and anti-PD-L1.

**Material and methods**

**TLR9 agonist**

Lefitolimod was synthesized as described previously by Mologen. In short, two identical 5’ phosphorylated, hairpin-shaped 58-mer ODN were ligated and the resulting dumbbell-shaped covalently closed molecules were purified by HPLC. Lefitolimod consists of a double-stranded stem and two single-stranded loops of 30 nucleotides each with three non-methylated CG motifs in each loop. Lefitolimod was dissolved in phosphate-buffered saline (15 mg/ml). Endotoxins were below 10 EU/mg.

**Mouse tumor models**

**Selection of tumor models**

The MoA of lefitolimod includes a strong activation of cells of the innate and adaptive immune system, necessary for an anti-tumor response, which should be applicable for different tumor types. To confirm this hypothesis, lefitolimod was tested in diverse tumor models covering a range of different tumor indications with diverse immunological background (including low-immunogeneic tumors). A summary table of the tumor models used is provided in the Supplement (Table S1).

**Syngeneic tumor models**

Female C57BL/6 and Balb/c mice (age 6–8 weeks) were housed and treated in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Tumors were engrafted by subcutaneous (sc) injection of 100–200 µl tumor cell suspension in the flank. Tumor length and width were determined using calipers and volume was calculated as (width² × length)/2). Animals were sacrificed when tumor size exceeded a predetermined endpoint.

**CT26 model for TME evaluation**

Sc tumor inoculation was done with 5 × 10⁴ CT26 cells (+50% matrigel). Begin of treatment with 200 or 250 µg lefitolimod (in PBS) or vehicle was started at day 10, when the mean tumor volume was about 140 mm³. In total, four intratumoral (itu) applications were performed, at day 10, 13, 15, and 17. At day 20 the tumors were sampled and subjected to immunohistochemistry (IHC) or tumor-infiltrating lymphocytes (TIL) were isolated and analyzed by FACS.

**B16 model:**

Tumor inoculation was done with 5 × 10⁵ B16 cells. Begin of treatment with 200 µg lefitolimod (in PBS) or vehicle was started at day 3. In total, nine sc applications were performed every other day. Tumor growth and survival were assessed.

**EMT-6 model**

Sc tumor inoculation was done with 5 × 10⁵ EMT-6 cells. Mice were randomized prior to treatment when tumors were well established (about 40 mm³). 250 µg lefitolimod (in PBS) or vehicle was given itu three times per week for 3 weeks. For
re-challenge experiments surviving mice were re-inoculated with $5 \times 10^5$ EMT-6 cells at day 54 and $5 \times 10^5$ CT26 cells at day 115 – distant from the primary tumor inoculation site, but without further treatment. Naïve mice were inoculated with tumor cells without any treatment as re-challenge controls.

**CT26 model, combination with aPD-L1**
Sc tumor inoculation was done with $1 \times 10^6$ CT26 cells. Mice were randomized prior to tumor inoculation according to their body weight. 250 µg lefitolimod (in PBS) or vehicle was given peritumorally three times per week (11 applications in total), starting at day 3. 10 mg/kg aPD-L1 (clone 10F.9G2 manufacturer: Bio X Cell) was given intraperitoneally (ip), two times per week for 4 weeks, starting at day 3. Tumor growth and survival (time to reach tumor volume of 1500 mm$^3$) were assessed.

**A20 model, combination with aPD-1**
Sc tumor inoculation was done with $1 \times 10^6$ A20 cells. Mice were randomized prior to tumor inoculation according to their body weight. 250 µg lefitolimod (in PBS) or vehicle was given peritumorally three times per week for 3 weeks with 11 applications in total, starting at day 14. 100 µg (per mouse) aPD-1 (clone RMP1-14, company Bio X Cell) was given ip, two times per week for 2 weeks, starting at day 8. Tumor growth and survival (time to reach tumor volume of 1800 mm$^3$) were assessed.
**De novo tumor model**

Skin painting studies are frequently used as an experimental carcinogenesis model based on OCDE Guideline 451 “Carcinogenicity studies” and NTP Guideline “Specifications for the conduct of studies to evaluate the toxic and carcinogenic potential of chemical, biological and physical agents in laboratory animals for the National Toxicology Program”. The two-step skin carcinogenesis model is defined by an irreversible tumor initiation process that often involves the activation of the c-H-ras oncogene, and tumor promotion caused by topical application of a promoting test substance. One hundred and fifty outbred female (hairless) SKH1 mice were grouped according to NTP-guidelines into three groups (50 mice each). A single dose of DMBA (7,12-Dimethylbenzanthracene) dissolved in acetone was applied to the back of each mouse (40 µg/mouse/application). As a promoter substance, TPA (12-O-tetradecanoylphorbol-13-acetate) was applied three times per week starting day 7. Lefitolimod (20 µg once-weekly) application was started in parallel and administered sc or ip in the respective group. Clinical observations, body weight, and skin tumors were recorded once a week. All surviving mice were sacrificed after 18 weeks. All mice sacrificed at that time and those that died during the application period were examined for skin tumors.

**Evaluation of tumor microenvironment (TME)**

The syngeneic colon carcinoma model CT26 was used to evaluate lefitolimod’s modulation of the TME. The localization of immune cells within the tumor was investigated by immunohistochemistry. The phenotype of T cells and macrophages present within tumor-infiltrating immune cells were analyzed by flow cytometry.

**Immunohistochemical (IHC) analysis of tumors**

Tumors were embedded in Tissue-TEK OCT (Sakura Finetek Inc.) and stored at −20°C or formalin-fixed paraffin-embedded (FFPE) sections were prepared. For the detection of CD8 + T cells 5 µm cryosections were prepared, fixed in acetone and stained using the Ventana Discovery XT system (Roche). Sections were incubated with Rat anti-mouse CD8alpha (clone 53–6,7, eBioscience) at a dilution 1:500 for 32 min. Thereafter, sections were incubated with Rabbit anti-Rat IgG Fc (clone R18-2, abcam) at a dilution 1/200. For the detection of F4/80+ macrophages in FFPE sections after a pre-treatment of slides for dewaxing and heat antigen retrieval with the Ventana Cell Conditioning Solution 1 (Roche) for 40 min, a rat anti-mouse CD3 antibody (clone CD3-12, Abcam,) was added for 60 min at a dilution 1/200. For the detection of F4/80+ macrophages in FFPE sections after a pre-treatment of slides for dewaxing and heat antigen retrieval with the Ventana Protease 3 (Roche) for 8 min, a rat anti-mouse F4/80 antibody (clone BM8, eBiosciences) was added for 60 min at a dilution 1/50. Sections for CD3- and CD8- and F4/80-staining were incubated with Rabbit anti-Rat IgG Fc (clone R18-2, abcam) at a dilution 1/500 for 32 min. Thereafter, sections were incubated with omniMap anti-RabbitHRP (Roche) for 16 min. The chromoMap DAB kit (Roche) was used as substrate for visualization. Counterstaining was performed with hematoxylin. Slides were scanned (NanoZoomer, Hamamatsu) and for CD8-staining tumor center and margin were manually scored by two experienced operators in a blinded fashion (1: no labeling, 2: few labeling, 3: intermediate labeling, 4: intense labeling). Quantification of the CD3+ cells within the tumor was performed using the Tissue studio™ software from Definiens®.

**Flow cytometry of tumor cells**

Single-cell suspensions of tumors from mice inoculated with CT26 tumor cells and treated itu with 250 µg lefitolimod (in PBS) or vehicle were prepared at day 20 after inoculation. Cells were surface-stained with monoclonal antibodies in PBS containing 3% serum on ice. The following antibodies were used: anti-CD4 (clone REA604), anti-CD8a (clone 53–6,7), anti-CD45 (clone 30-F11), anti-Thy1 (clone 5E10), anti-FOXP3 (clone FJK-16s), anti-Granzyme B (clone GB11), anti-CD69 (clone H1.2F3), anti-F4/80 (clone T45-234), anti-Ly6C (clone AL-21), anti-CD11b (clone M1/70), anti-Gr1 (clone M1/70), anti-MHC II (clone M5/114.15.2) and anti-CD86 (clone GL1). All flow cytometry parameters of cells were acquired on a FACS Canto II (BD Biosciences). Percentages of cell subsets were related to the indicated parent populations; geometric means of fluorescence for markers were indicated as mean fluorescence intensity (MFI). Data were analyzed with the BD FACSDiva software.

**Elispot assay**

Splenocytes from mice sc inoculated with CT26 tumor cells and itu treated with 250 µg lefitolimod (in PBS) or vehicle were prepared at day 20 after inoculation. 9 × 10^7 splenocytes were ex vivo stimulated with 1 × 10^6 CT26 cells or 1 µg/ml MHC I-restricted AH1 peptide (Eurogentec) for 20 h at 37°C. As a positive control for polyclonal T-cell responsiveness, splenocytes were stimulated with 0.5 µg/ml of anti-mouse CD3 antibody (clone 145-2C11, BD Biosciences). The frequency of IFN-gamma secreting cells was determined in triplicates using an IFN-gamma ELISPOT assay (Mabtech), according to the manufacturer’s protocol. Spot-forming cells were counted using an automated ELISpot reader system (Biosys).

Spleen cells of nine mice surviving double EMT-6 tumor inoculation as well as CT26 tumor inoculation and spleen cells from three naïve mice were prepared. For ELISPOT assay (Mabtech, No. 3321-4HPW-2) 8 × 10^6 spleen cells were co-cultured with 8 × 10^6 mitomycin C-treated (100 µg/ml) tumor cells (EMT-6, CT26, Renca, A20, 4T-1, WEHI164) for 24 h in triplicates. Detection of IFN-gamma secreting cells was done according to the instructions of the manufacturer. For positive controls spleen cells were incubated with 500 ng/ml PMA plus 1 µg/ml Ionomycin; for negative controls, spleen cells were cultured without any additives. Number of spots was analyzed in an ELISpot reader (AID iSpot). For analysis number of spots in the “spleenocytes only” approach was subtracted from the respective approaches with tumor cells.

**In vitro PBMC stimulation assay**

Buffy coats from anonymized healthy donors were obtained from the “DRK-Blutspendedienst – Ost”. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation using Ficoll (Biochrom). Cells were cultured in complete medium (RPMI1640 [Lonza] with 2 mM UltraGlutamine [Lonza]
supplemented with 10% [v/v] fetal calf serum [Linaris], 100 U/ml Penicillin and 100 µg/ml Streptomycin [Lonza] in flat-bottom plates (PBMC, 6 million cells/ml). Cells were stimulated with 1 µg/ml extended CEF (cytomegalovirus, Epstein-Barr virus, influenza virus) peptide pool (JPT Peptide Technologies GmbH), 3 µM leflomilid and 10 µg/ml anti-PD-1 (Milenyi Biotec) for 2 days. IFN-gamma in the culture supernatant was determined by ELISA (OptEIA Human IFN gamma ELISA Set, BD Biosciences) and was performed in duplicates according to the manufacturer’s instructions. Optical density was measured at 450 nm; the data were analyzed with the MicroWin software (Berthold Technologies).

Statistical analyses

Data were analyzed with GraphPad Prism 7 (GraphPad Software Inc.). P values <0.05 were considered significant. The statistical analyses are specified in the figure legends.

Acknowledgments

We are grateful to Jaqueline Schneider and Lisa Schneider for their expert technical assistance.

Disclosure of interest

KK, BV, DO, MB and MS are employees at Mologen AG. BW holds shares of Mologen AG and receives compensation for consulting services.

References

1. Connolly DJ, O’Neill LA. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol. 2012;12:510–518. doi:10.1016/j.coph.2012.06.002.
2. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer GTrial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1:699–716. doi:10.4161/onci.20696.
3. Kanzler H, Barrat FJ, Hessels EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552–559. doi:10.1038/nm1589.
4. Hornung V, Rothenfuss S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. Quantitative expression of peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531–4537. doi:10.4049/jimmunol.168.9.4531.
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune response. Nat Immunol. 2004;5:987–995. doi:10.1038/ni1112.
6. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4:249–258. doi:10.1038/nri1329.
7. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117:1184–1194. doi:10.1172/JCI31414.
8. Kapp K, Kleuss C, Schroff M, Wittig B. Genuine immunomodulation with dSLIM, Mol Ther Nucleic Acids. 2014;3:e170. doi:10.1038/mtna.2014.28.
9. Schmidt M, Hagner N, Marco A, Konig-Merediz SA, Schroff M, Wittig B. Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703. Nucleic Acid Ther. 2015;25:130–140. doi:10.1089/nat.2015.0533.
10. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol Hematol. 2015;94:31–44. doi:10.1016/j.critrevonc.2014.12.002.
11. Cunningham D, Van Cutsem E, Salazar R, Ducreux M, Scheithauer W, Scalfani F, Wiegert E, Schmidt M, Tomaszewski C, Sobiroz A. et al. Patient characteristics after completion of recruitment from the phase 3 IMPULSE study with leflomilid in metastatic colorectal carcinoma. Ann Oncol TIP. 2017;28:93. doi:10.1093/annonc/mdy107.
12. Schmoll HJ, Wittig B, Arnold D, Riera-Knorrrenschild J, Nitsche D, Kroening H, Mayer F, Andel J, Ziebermayer R, Scheithauer W. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014;140:1615–1624. doi:10.1007/s00432-014-1682-7.
13. Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Domine Gomez M, et al. Immunotherapeutic maintenance treatment with Toll-like receptor 9 agonist leflomilid in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase 2 IMPULSE study. Ann Oncol. 2018. doi:10.1093/annonc/mdy326.
14. Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med. 2009;265:43–57. doi:10.1111/j.1365-2796.2008.02050.x.
15. Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24–32. doi:10.1016/j.smim.2006.12.004.
16. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219–1226. doi:10.1038/nri1141.
17. Schmidt M, Anton K, Nordhaus C, Junghans H, Wittig B, Worm M. Cytokine and Ig-production by GC-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy. 2006;61:56–63. doi:10.1111/j.1398-9995.2005.00908.x.
18. Kapp K, Schneider J, Schneider L, Gollinge N, Jansch S, Schroff M, Wittig B, Kleuss C. Distinct immunological activation profiles of dSLM® and ProMune® depend on their different structural context. Immun Inflamm Dis. 2016;4:446–462. doi:10.1002/iiid.3126.
19. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–1086. doi:10.1158/2159-8290.CD-18-0367.
20. Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Efremova M, Rieder D, Klepsch V, Charoentong P, Finotello F, Hackl H, Herrmann-Kleiter N, Lower M, Baier G, Krogsdam A, et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat Commun. 2018;9:32. doi:10.1038/s41467-017-02442-0.
21. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013;36:477–489. doi:10.1097/CJI.0b013e31826f75f5.
22. Yu JW, Bhattacharya S, Yanamandra N, Kiliian D, Shi H, Yadavilli S, Katiinskyaya Y, Kazchynski H, Conner M, Benson W, et al. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS One. 2018;13:e0206233. doi:10.1371/journal.pone.0206233.
contributing to exclusion of T cells. Nature. 2018;554:544–548. doi:10.1038/nature25501.

25. Fuertes MB, Kach A, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8[alpha]+ dendritic cells. J Exp Med. 2011;208:2005–2016. doi:10.1084/jem.20110159.

26. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinie U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003. doi:10.1084/jem.20110158.

27. van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries JMJ. Migrating into the tumor: a roadmap for T cells. Trends Cancer. 2017;3:797–808. doi:10.1016/j.trecan.2017.09.006.

28. Nagarsheth N, Wicha MS, Zou W. Chemoskines in the cancer microenvironment and their relevance in cancer immunotherapy, Nat Rev Immunol. 2017;17:559–572. doi:10.1038/nri.2017.49.

29. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31. doi:10.1007/978-3-319-67577-0_2.

30. Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28:383–391. doi:10.1093/intimm/dxw014.

31. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233–1247. doi:10.1016/j.cell.2016.01.049.

32. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–150. doi:10.1038/s41568-019-0116-x.

33. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–287. doi:10.1038/nrc.2016.36.

34. Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner J, Fu M, Messer KS, Guiducci C, et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017;2. doi:10.1172/jci.insight.93997.

35. Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, Coffman RL, Guiducci C. Intra-tumoral injection of a CpG oligonucleotide reverses resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113: E2740–E29. doi:10.1073/pnas.1608555113.

36. Ribas A, Medina T, Kummars A, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Discov. 2018;8:1250–1257. doi:10.1158/2159-8290.CD-18-0280.

37. Weihrauch MR, Richly H, von Bergwelt-Baldon MS, Becker HJ, Schmidt M, Hacker UT, Shimabukuro-Voßhagen A, Holtick U, Nokay B, Schroff M, et al. Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors. Eur J Cancer. 2015;51:146–156. doi:10.1016/j.ejca.2014.11.002.

38. Reilley M, Tsimberidou A, Pihl-Paul S, Yap T, Fu S, Naing A, Rodon J, Nguyen L, Ager C, Meng M, et al. Phase 1 trial of TL9R agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. J Clin Oncol. 2019;37. abstractTPS2669. doi:10.1200/JCO.2019.37.13_suppl.TPS2669.

39. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015;212:435–445. doi:10.1084/jem.20150295.

40. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585–600. doi:10.1007/s00281-013-0367-7.

41. Cassettà L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17:887–904. doi:10.1038/nrd.2018.169.

42. Zheng X, Turkovski K, Mora J, Bruné B, Seeger W, Weigert A, Savi R. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8:48436–48452. doi:10.18632/oncotarget.17061.

43. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becker B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018. doi:10.1038/nm.4956.

44. Romano E, Kusio-Kobiáš M, Foukas PG, Baumgartner P, Meyer C, Ballabeni P, Michelin O, Weide B, Romero P, Speiser DE. Ipiñumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112:6410–6415. doi:10.1073/pnas.141720112.

45. Kucynski EA, Krueger J, Chow A, Xu P, Man S, Sundaravadan Y, Miller JK, Krzyzanowski PM, Kerbel RS. Impact of chemical-induced mutational load increase on immune checkpoint therapy in poorly responsive murine tumors. Mol Cancer Ther. 2018;17:869–882. doi:10.1158/1535-7163.MCT-17-1091.

46. Mangibye SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010;33:225–235. doi:10.1097/CJI.0b013e3181c101cb.

47. Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20:1747–1756. doi:10.1158/1078-0432.CCR-13-2116.

48. Marabelle A, Tsilikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28:xii33–xii43. doi:10.1093/annonc/mdx683.

49. Ellmark P, Mangibye SM, Furebring C, Norlen P, Totterman TH. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother. 2017;66:1–7. doi:10.1007/s00262-016-1909-3.

50. Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018;29:2163–2174. doi:10.1093/annonc/mdy423.

51. Kratup AR, Abdel-Mohsen M, Schleimann MH, Vihholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A, et al. The TL9R agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunol. 2017. doi:10.1038/mi.2017.59.

52. Zitvogel L, Pitt JM, Dailiere R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16:759–773. doi:10.1038/nrc.2016.91.